HopeMed Hopes For First-Line Inroads In Endometriosis-Associated Pain

 
• By Dexter Jie Yan

Interim results from an international Phase II study with its prolactin inhibiting antibody have boosted HopeMed’s confidence in its first-line potential in the chronic disorder, the Chinese venture's CEO tells Scrip.

Women's health
Hope Medicine hopes its HMI-115, a prolactin inhibitor, could tackle endometriosis-associated pain in the first-line setting. • Source: Shutterstock

With positive interim results from a global Phase II study in hand, the management at Hope Medicine (HopeMed), a Chinese biotech specialized in women’s health, is entertaining hopes of a first-line treatment for endometriosis-associated pain.

The firm’s lead asset is HMI-115, a once-biweekly, subcutaneously administered antibody that

Key Takeaways
  • Chinese women's health biotech HopeMed has reported positive top-line interim results from a global Phase II clinical study in endometriosis-associated pain with HMI-115, a potentially first-in-class prolactin inhibitor.
  • HopeMed CEO Nathan Chen believes the molecule's major strength is its safety for first-line use

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip